NZ752443A - Lasofoxifene treatment of er+ breast cancer - Google Patents
Lasofoxifene treatment of er+ breast cancerInfo
- Publication number
- NZ752443A NZ752443A NZ752443A NZ75244317A NZ752443A NZ 752443 A NZ752443 A NZ 752443A NZ 752443 A NZ752443 A NZ 752443A NZ 75244317 A NZ75244317 A NZ 75244317A NZ 752443 A NZ752443 A NZ 752443A
- Authority
- NZ
- New Zealand
- Prior art keywords
- breast cancer
- lasofoxifene
- treatment
- estrogen receptor
- endocrine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ793063A NZ793063B2 (en) | 2017-10-10 | Lasofoxifene treatment of er+ breast cancer |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662406859P | 2016-10-11 | 2016-10-11 | |
| US201762457759P | 2017-02-10 | 2017-02-10 | |
| US201762502299P | 2017-05-05 | 2017-05-05 | |
| PCT/US2017/055970 WO2018093484A1 (en) | 2016-10-11 | 2017-10-10 | Lasofoxifene treatment of er+ breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ752443A true NZ752443A (en) | 2022-11-25 |
Family
ID=60186386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ752443A NZ752443A (en) | 2016-10-11 | 2017-10-10 | Lasofoxifene treatment of er+ breast cancer |
Country Status (20)
| Country | Link |
|---|---|
| US (8) | US20180098963A1 (enExample) |
| EP (2) | EP4035662A1 (enExample) |
| JP (4) | JP6892151B2 (enExample) |
| KR (5) | KR102462433B1 (enExample) |
| CN (3) | CN110099680B (enExample) |
| AU (3) | AU2017360365B2 (enExample) |
| BR (1) | BR112019007254A2 (enExample) |
| CA (1) | CA3040266A1 (enExample) |
| DK (1) | DK3525774T3 (enExample) |
| ES (1) | ES2909576T3 (enExample) |
| IL (2) | IL284875B (enExample) |
| MX (2) | MX387856B (enExample) |
| NZ (1) | NZ752443A (enExample) |
| PL (1) | PL3525774T3 (enExample) |
| PT (1) | PT3525774T (enExample) |
| RU (1) | RU2019114079A (enExample) |
| SG (2) | SG10201913951YA (enExample) |
| TW (4) | TWI896001B (enExample) |
| WO (2) | WO2018071440A1 (enExample) |
| ZA (1) | ZA201902454B (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11974983B2 (en) | 2018-04-10 | 2024-05-07 | Duke University | Lasofoxifene treatment of breast cancer |
| US11980597B2 (en) | 2016-10-11 | 2024-05-14 | Duke University | Lasofoxifene treatment of breast cancer |
| US12023321B2 (en) | 2021-11-18 | 2024-07-02 | Sermonix Pharmaceuticals, Inc. | Lasofoxifene treatment of aromatase-resistant ER+cancer |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105816437B (zh) | 2016-03-29 | 2018-08-03 | 深圳市药欣生物科技有限公司 | 一种帕布昔利布的药物制剂及其制备方法 |
| CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
| JP2025517483A (ja) * | 2022-05-25 | 2025-06-05 | サーモニックス ファーマシューティカルズ， インコーポレイテッド | Ｃｄｋ４／６阻害剤で進行したｅｒ＋乳がんのラソフォキシフェン併用処置 |
| WO2025075631A1 (en) | 2023-10-06 | 2025-04-10 | Sermonix Pharmaceuticals, Inc. | Lasofoxifene treatment of endocrine therapy resistant er+ cancer |
| MX2023013107A (es) * | 2023-11-06 | 2025-06-02 | Centro De Investig Y De Estudios Avanzados Del I P N | Composiciones sinergicas de loratadina-raloxifeno-sorafenib para el tratamiento de cancer hepatico. |
| WO2025122504A1 (en) * | 2023-12-04 | 2025-06-12 | Foundation Medicine, Inc. | Esr1 mutations, esr1 co-occurring mutations, and uses thereof |
| WO2025165887A1 (en) * | 2024-01-30 | 2025-08-07 | Sermonix Pharmaceuticals, Inc. | Lasofoxifene treatment of er+ cancers with constitutively active esr1 mutations |
| CN119842900A (zh) * | 2025-01-17 | 2025-04-18 | 厦门飞朔生物技术有限公司 | 一种可用于乳腺癌内分泌耐药治疗指导的人esr1基因突变检测试剂盒 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| UA51676C2 (uk) | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
| IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
| HN1996000101A (es) | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
| US20040044080A1 (en) | 1997-10-28 | 2004-03-04 | Place Virgil A. | Treatment of dyspareunia with topically administered nitroglycerin formulations |
| WO1999065498A1 (en) | 1998-06-19 | 1999-12-23 | Senju Pharmaceutical Co., Ltd. | Agents for relieving side effects of adrenal cortex hormone |
| YU26700A (sh) | 1999-05-24 | 2002-06-19 | Pfizer Products Inc. | Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin |
| EP1086692A3 (en) | 1999-07-28 | 2003-07-09 | Pfizer Products Inc. | Estrogen agonists and antagonists for multiple indications |
| US6436977B1 (en) | 1999-09-29 | 2002-08-20 | Pfizer Inc. | Dosing regimens for lasofoxifene |
| CO5271697A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona |
| BR0108107A (pt) | 2000-01-28 | 2003-03-11 | Endorech Inc | Moduladores seletivos dos receptores de estrogênio em combinação com estrogênios; kits e composições farmacêuticas para praticar tal combinação; bem como a administração da referida combinação |
| DE10039199A1 (de) | 2000-08-10 | 2002-02-21 | Schering Ag | Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen |
| JP2004507465A (ja) | 2000-08-11 | 2004-03-11 | ワイス | エストロゲン受容体陽性癌腫の治療方法 |
| WO2002056903A2 (en) | 2001-01-17 | 2002-07-25 | Praecis Pharmaceuticals Inc. | Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators |
| AU781168B2 (en) | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
| RU2278861C2 (ru) | 2002-03-28 | 2006-06-27 | Пфайзер Продактс Инк. | Очищенный лазофоксифен и способ очистки рацемического лазофоксифена рекристаллизацией |
| PA8576201A1 (es) | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco |
| US8835413B2 (en) | 2004-10-20 | 2014-09-16 | Endorecherche, Inc. | Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women |
| US20090012052A1 (en) | 2006-11-09 | 2009-01-08 | Ore Pharmaceuticals Inc. | Method for treating er+ breast cancer |
| US20110015134A1 (en) | 2007-04-16 | 2011-01-20 | Retsky Michael W | Method of treatment for early stage cancer |
| CZ2007373A3 (cs) | 2007-05-29 | 2008-12-10 | Zentiva, A. S | Zpusob prípravy lasofoxifenu |
| CA2725390C (en) | 2008-04-08 | 2014-09-23 | Syndax Pharmaceuticals, Inc. | Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer |
| WO2009137543A2 (en) * | 2008-05-06 | 2009-11-12 | Ore Pharmaceuticals Inc. | Methods for breast cancer screening and treatment |
| CN102405047B (zh) | 2009-01-30 | 2014-07-09 | 葛兰素史密斯克莱有限责任公司 | 结晶型的n-{(1s)-2-氨基-1-[(3-氟苯基)甲基]乙基}-5-氯-4-(4-氯-1-甲基-1h-吡唑-5-基)-2-噻吩甲酰胺盐酸盐 |
| EP2239570A1 (en) * | 2009-04-10 | 2010-10-13 | PamGene B.V. | Method for determining the estrogen receptor status of breast cancer |
| MX373926B (es) * | 2009-05-27 | 2020-07-10 | Ptc Therapeutics Inc | Metodos para tratar cancer y estados no neoplasicos. |
| US20130253035A1 (en) | 2010-08-16 | 2013-09-26 | Duke University | Camkk-beta as a target for treating cancer |
| US20120052508A1 (en) * | 2010-08-27 | 2012-03-01 | Rutgers, The State University Of New Jersey | Genetic markers and diagnostic methods for resistance of breast cancer to hormonal therapies |
| US20140134170A1 (en) | 2011-03-11 | 2014-05-15 | Merrimack Pharmaceuticals, Inc. | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |
| AU2012255920A1 (en) | 2011-05-18 | 2013-11-07 | Merck Sharp & Dohme Corp. | Therapeutic anti-IGF1R combinations |
| WO2013056178A2 (en) * | 2011-10-14 | 2013-04-18 | Foundation Medicine, Inc. | Novel estrogen receptor mutations and uses thereof |
| EP2791128A4 (en) | 2011-12-16 | 2015-04-22 | Olema Pharmaceuticals Inc | NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF |
| US20160038506A1 (en) | 2012-02-14 | 2016-02-11 | Repros Therapeutics Inc. | Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof |
| US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
| US9204286B1 (en) | 2013-03-15 | 2015-12-01 | Sprint Communications Company L.P. | System and method of branding and labeling a mobile device |
| SG11201607339VA (en) * | 2014-03-13 | 2016-10-28 | Hoffmann La Roche | Methods and compositions for modulating estrogen receptor mutants |
| WO2015136016A2 (en) | 2014-03-13 | 2015-09-17 | F. Hoffmann-La Roche Ag | Therapeutic combinations with estrogen receptor modulators |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| ES3055185T3 (en) | 2014-03-28 | 2026-02-10 | Univ Duke | Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator |
| CN113101292B (zh) | 2014-05-08 | 2023-07-11 | 上海市生物医药技术研究院 | 双炔失碳酯组合物和疾病治疗方法 |
| KR20170078811A (ko) | 2014-11-07 | 2017-07-07 | 리폭센 테크놀로지즈 리미티드 | 원발성 호르몬 저항성 자궁내막암 및 유방암 치료 방법 |
| AU2016247674A1 (en) | 2015-04-14 | 2017-10-19 | Atossa Genetics Inc. | Compositions and methods of treatment of breast disorders and estrogen-related disorders |
| KR20250152679A (ko) * | 2015-04-29 | 2025-10-23 | 래디어스 파마슈티컬스, 인코포레이티드 | 암을 치료하는 방법 |
| WO2018071437A1 (en) | 2016-10-11 | 2018-04-19 | Sermonix Pharmaceuticals, Llc | Lasofoxifene treatment of vva and osteoporosis in survivors of breast cancer and other malignancies |
| ES2909576T3 (es) | 2016-10-11 | 2022-05-09 | Univ Duke | Tratamiento con lasofoxifeno del cáncer de mama ER+ |
| CN115737637A (zh) | 2017-01-10 | 2023-03-07 | 王巍 | 拉索昔芬调节膜结合雌激素信号的应用及治疗癌症的方法 |
| US11497730B2 (en) | 2018-04-10 | 2022-11-15 | Duke University | Lasofoxifene treatment of breast cancer |
| JP7571006B2 (ja) * | 2018-08-17 | 2024-10-22 | ジェネンテック， インコーポレイテッド | 乳がんの処置のための診断的および治療的方法 |
| EP4412649A4 (en) | 2021-10-05 | 2025-11-05 | Univ Duke | Compositions containing small molecule tumor immunity regulators and their methods of use |
| GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
| JP2025517483A (ja) | 2022-05-25 | 2025-06-05 | サーモニックス ファーマシューティカルズ， インコーポレイテッド | Ｃｄｋ４／６阻害剤で進行したｅｒ＋乳がんのラソフォキシフェン併用処置 |
-
2017
- 2017-10-10 ES ES17791239T patent/ES2909576T3/es active Active
- 2017-10-10 RU RU2019114079A patent/RU2019114079A/ru unknown
- 2017-10-10 KR KR1020217023829A patent/KR102462433B1/ko active Active
- 2017-10-10 DK DK17791239.1T patent/DK3525774T3/da active
- 2017-10-10 US US15/729,320 patent/US20180098963A1/en not_active Abandoned
- 2017-10-10 NZ NZ752443A patent/NZ752443A/en unknown
- 2017-10-10 KR KR1020247000452A patent/KR20240007720A/ko active Pending
- 2017-10-10 JP JP2019540308A patent/JP6892151B2/ja active Active
- 2017-10-10 KR KR1020197013405A patent/KR102285453B1/ko active Active
- 2017-10-10 SG SG10201913951YA patent/SG10201913951YA/en unknown
- 2017-10-10 WO PCT/US2017/055974 patent/WO2018071440A1/en not_active Ceased
- 2017-10-10 IL IL284875A patent/IL284875B/en unknown
- 2017-10-10 KR KR1020237008605A patent/KR102531354B1/ko active Active
- 2017-10-10 CN CN201780073528.3A patent/CN110099680B/zh active Active
- 2017-10-10 MX MX2019004184A patent/MX387856B/es unknown
- 2017-10-10 SG SG11201903236SA patent/SG11201903236SA/en unknown
- 2017-10-10 AU AU2017360365A patent/AU2017360365B2/en active Active
- 2017-10-10 CN CN202110143863.4A patent/CN112933082A/zh active Pending
- 2017-10-10 PT PT177912391T patent/PT3525774T/pt unknown
- 2017-10-10 PL PL17791239T patent/PL3525774T3/pl unknown
- 2017-10-10 EP EP21215433.0A patent/EP4035662A1/en active Pending
- 2017-10-10 WO PCT/US2017/055970 patent/WO2018093484A1/en not_active Ceased
- 2017-10-10 BR BR112019007254-3A patent/BR112019007254A2/pt not_active Application Discontinuation
- 2017-10-10 US US16/341,033 patent/US20190231718A1/en not_active Abandoned
- 2017-10-10 EP EP17791239.1A patent/EP3525774B1/en active Active
- 2017-10-10 CA CA3040266A patent/CA3040266A1/en active Pending
- 2017-10-10 CN CN202011320148.5A patent/CN112353796A/zh active Pending
- 2017-10-10 KR KR1020227037620A patent/KR102623130B1/ko active Active
- 2017-10-11 TW TW113106582A patent/TWI896001B/zh active
- 2017-10-11 TW TW106134805A patent/TWI729227B/zh active
- 2017-10-11 TW TW110124571A patent/TWI790672B/zh active
- 2017-10-11 TW TW111149243A patent/TWI836808B/zh active
-
2018
- 2018-03-28 US US15/939,218 patent/US10258604B2/en active Active
-
2019
- 2019-02-01 US US16/265,109 patent/US10905659B2/en active Active
- 2019-04-10 MX MX2021013911A patent/MX2021013911A/es unknown
- 2019-04-10 IL IL265938A patent/IL265938B/en unknown
- 2019-04-17 ZA ZA2019/02454A patent/ZA201902454B/en unknown
-
2020
- 2020-10-16 US US17/073,253 patent/US20210361596A1/en not_active Abandoned
-
2021
- 2021-02-16 JP JP2021022514A patent/JP7247241B2/ja active Active
-
2022
- 2022-10-09 AU AU2022246480A patent/AU2022246480B2/en active Active
-
2023
- 2023-01-13 JP JP2023003699A patent/JP7418052B2/ja active Active
- 2023-03-30 US US18/193,207 patent/US11980597B2/en active Active
- 2023-12-26 JP JP2023219161A patent/JP7774896B2/ja active Active
-
2024
- 2024-04-08 US US18/629,894 patent/US20250064757A1/en active Pending
- 2024-07-04 US US18/764,274 patent/US12414924B2/en active Active
-
2025
- 2025-01-16 AU AU2025200327A patent/AU2025200327B2/en active Active
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11980597B2 (en) | 2016-10-11 | 2024-05-14 | Duke University | Lasofoxifene treatment of breast cancer |
| US12414924B2 (en) | 2016-10-11 | 2025-09-16 | Duke University | Lasofoxifene treatment of breast cancer |
| US11974983B2 (en) | 2018-04-10 | 2024-05-07 | Duke University | Lasofoxifene treatment of breast cancer |
| US12023321B2 (en) | 2021-11-18 | 2024-07-02 | Sermonix Pharmaceuticals, Inc. | Lasofoxifene treatment of aromatase-resistant ER+cancer |
| US12433866B2 (en) | 2021-11-18 | 2025-10-07 | Sermonix Pharmaceuticals, Inc. | Lasofoxifene treatment of aromatase-resistant ER+ cancer |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ752443A (en) | Lasofoxifene treatment of er+ breast cancer | |
| MX2024000253A (es) | Inhibicion del smarca2 para el tratamiento del cancer. | |
| SG10201806656UA (en) | Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer | |
| MX2016011698A (es) | Metodos y composiciones para modular mutantes de receptor de estrogeno. | |
| EP4589014A3 (en) | Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden | |
| IL273782A (en) | Compositions of cells and bacteria for the treatment of colon cancer and methods for evaluating prognosis for these patients | |
| MY186977A (en) | Tetrasubstituted alkene compounds and their use | |
| IL260935A (en) | Methods for treating hrg, her2-, er breast cancer using combined treatments that include an anti-erbb3 antibody | |
| PH12016502354A1 (en) | Pharmaceutical composition | |
| LT3806898T (lt) | Gremlin-1 antagonistas, skirtas naudoti vėžio gydymui | |
| MX2016002273A (es) | Tratamiento de cancer con una combinacion de un antagonista de proteina de muerte programada 1 y dinaciclib. | |
| MX2016002051A (es) | Metodos y kits para la subtipificacion molecular de tumores. | |
| EP4691562A3 (en) | Anti-pd-l1 combinations for treating tumors | |
| MX2018008427A (es) | Combinaciones anti-cd20 para tratar tumores. | |
| IL276748A (en) | Methods for the detection and treatment of prostate cancer | |
| MX388166B (es) | Metodos para tratar canceres de mama metastasicos o localmente avanzados con antagonistas de union al eje de pd-1 y taxanos | |
| MX2016014007A (es) | Metodos para el tratamiento de cancer de mama temprano con trastuzumab-emtansina(mcc-dm1) y pertuzumab. | |
| GB201806064D0 (en) | Improved Classification And Prognosis Of Prostate Cancer | |
| SG11202007414XA (en) | Osimertinib for use in the treatment of non-small cell lung cancer | |
| SG11202106295WA (en) | Compositions and methods for cancer therapy | |
| IL284850A (en) | Methods of treating breast cancer with toctinib | |
| IL280830A (en) | Bracelets for use in cancer treatment methods | |
| PH12018502360A1 (en) | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers | |
| SG11202007005UA (en) | Use of crassocephalum rabens extract in the treatment of breast cancer | |
| NZ742470A (en) | Combination therapy for cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 OCT 2024 BY COMPUTER PACKAGES INC Effective date: 20230917 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 OCT 2025 BY COMPUTER PACKAGES INC Effective date: 20240917 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 OCT 2026 BY CHRIS REVIE Effective date: 20250917 |